1. Summary of participants in the studies.
|
Total No. |
Participants per group |
Mean age (years) |
Mean total prior miscarriages/woman |
aCL IgM | aCL IgG | LAC | aCL and LAC | aβ2GPI | |||||||||
| Studies | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | |
| Alalaf 2012 | 141 | 80 | 61 | 31.4 ± 5.8 | 30.6 ± 6.3 | 3.3 ± 1.7 | 3.4 ± 1.8 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Bao 2017 | 1015 | 497 | 518 | median 35 (25‐47) | median 34 (24‐43) | median 4 (2‐11) | median 3 (2‐8) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Farquharson 2002 | 98 | 51 | 47 | 33 ± 4.8 | 33 ± 4.9 | 3 ± 0.8 | 3 ± 0.9 | 3/51 | 5/47 | 6/51 | 2/47 | 23/51 | 18/47 | 18/51 | 22/47 | NA | NA |
| Fouda 2010 | 60 | 30 | 30 | 27.1 ± 3.7 | 28.9 ± 4.2 | 4.0 ± 1.2 | 4.1 ± 1.1 | 4/30 | 5/30 | 8/30 | 6/30 | 10/30 | 9/30 | 8/30 | 10/30 | NA | NA |
| Fouda 2011 | 60 | 30 | 30 | 27.5 ± 3.2 | 28.6 ± 3.5 | 4.4 ± 1.2 | 4.2 ± 1.2 | 5/30 | 8/30 | 7/30 | 5/30 | 12/30 | 10/30 | 6/30 | 7/30 | NA | NA |
| Kutteh 1996a | 50 | 25 | 25 | 33.2 ± 4.2 | 33.5 ± 5.8 | 3.9 ± 1.4 | 3.7 ± 1.0 | 6/25 | 5/25 | NR | NR | NA | NA | NA | NA | NA | NA |
| Kutteh 1996b | 50 | 25 | 25 | 33.3 ± 4.2 | 33.2 ± 3.9 | 3.9 ± 1.4 | 3.6 ± 1.0 | NR | NR | NR | NR | NA | NA | NA | NA | NA | NA |
| Laskin 2009* | 42 | 22 | 20 | 34.6 ± 3.9 | 33.8 ± 4.1* | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NA | NA |
| Pattison 2000 | 40 | 20 | 20 | 31 ± 4.5 | 30.9 ± 3.9 | NR | NR | 6/20 | 3/20 | 6/20 | 9/20 | 4/20 | 5/20 | 3/20 | 3/20 | NA | NA |
| Rai 1997 | 90 | 45 | 45 | median 32 (23‐40) |
median 34 (22‐44) |
median 4 (3‐15) |
median 4 (3‐8) |
0/45 | 1/45 | 3/45 | 4/45 | 40/45 | 34/45 | 6/45 | 2/45 | NA | NA |
| Stephenson 2004** | 26 | 13 | 13 | 34 (27‐40) | 34 (28‐43) | 3.8 (3‐7) | 3.9 (3‐7) | 4/14 | 11/14 | 11/14 | 7/14 | 6/14 | 3/14 | 4/14 | 2/14 | NA | NA |
aβ2GPI: anti‐β2‐glycoprotein‐I antibodies; aCL: anticardiolipin antibodies,aPL: antiphospholipid antibodies; LAC: lupus anticoagulant,.LMWH: low‐molecular weight heparin; NA: outcome not assessed;NR: outcome not reported,UFH: unfractionated heparin
* mean age in years for the entire study population (N = 88), not separately reported for the subgroup with positive aPL specifically.
** aPL profiles given for entire study population (N = 28), not separately reported the subgroup of patients who conceived and were subsequently randomised.
- Alalaf 2012: group A = LMWH, group B = aspirin
- Bao 2017: group A = LMWH + aspirin, group B = aspirin
- Farquharson 2002: group A = LMWH + aspirin, group B = aspirin
- Fouda 2010: group A = high‐dose LMWH plus aspirin, group B = low‐dose LMWH plus aspirin;
- Fouda 2011: group A = LMWH + aspirin, group B = UFH + aspirin
- Kutteh 1996a: group A = UFH + aspirin, group B = aspirin
- Kutteh 1996b: group A = high‐dose UFH plus aspirin, group B = low‐dose UFH + aspirin
- Laskin 2009: group A = LMWH + aspirin, group B = aspirin
- Pattison 2000: group A = aspirin, group B = placebo
- Rai 1997: group A = UFH + aspirin, group B = aspirin
- Stephenson 2004: group A = LMWH + aspirin, group B = UFH + aspirin